| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| PVP-I(元) | 68,618,506.55 | 30,820,504.31 | 67,920,808.14 | 35,499,479.55 |
| PVPK30(元) | 551,565,832.35 | 286,638,317.44 | 592,230,533.52 | 284,591,999.25 |
| 分子诊断服务(元) | 32,019,837.88 | 15,966,796.89 | 33,054,236.44 | 15,229,395.07 |
| 基因检测技术服务(元) | 61,057,951.37 | 32,699,580.33 | 65,711,389.79 | 29,243,570.25 |
| 欧瑞姿系列(元) | 156,792,205.77 | 77,096,450.36 | 158,214,628.66 | 68,961,884.31 |
| 医疗服务(元) | 62,632,595.33 | 39,082,167.38 | 61,058,495.68 | 23,633,012.47 |
| PVP系列其他产品(元) | 602,166,836.65 | 273,703,118.97 | 467,023,841.58 | 202,876,860.62 |
| 肿瘤早期诊断(元) | 48,564,077.07 | 23,006,827.88 | 40,479,972.05 | 18,391,705.83 |
| 生命科学研究试剂(元) | - | - | - | - |
| 其他主营业务(元) | - | - | - | 18,391,705.83 |
| 营业成本(元) | ||||
| PVP-I(元) | 41,393,772.57 | 19,440,327.07 | 40,178,294.71 | 19,795,863.50 |
| PVPK30(元) | 255,414,651.27 | 126,741,803.50 | 335,618,580.84 | 185,043,499.01 |
| 分子诊断服务(元) | 20,498,427.39 | 9,946,292.42 | 23,520,059.21 | 10,836,296.22 |
| 基因检测技术服务(元) | 47,233,202.06 | 21,748,696.59 | 54,069,351.01 | 24,134,748.51 |
| 欧瑞姿系列(元) | 38,279,962.64 | 27,015,129.50 | 44,754,207.76 | 23,977,351.21 |
| 医疗服务(元) | 45,491,934.28 | 29,603,830.03 | 45,685,360.48 | 18,483,357.22 |
| PVP系列其他产品(元) | 221,791,923.97 | 79,236,639.07 | 234,404,126.21 | 74,536,397.58 |
| 肿瘤早期诊断(元) | 18,927,079.20 | 8,952,883.51 | 16,833,471.54 | 7,577,607.42 |
| 生命科学研究试剂(元) | - | - | - | - |
| 其他主营业务(元) | - | - | - | 7,577,607.42 |
| 毛利(元) | ||||
| PVP-I(元) | 27,224,733.98 | 11,380,177.24 | 27,742,513.43 | 15,703,616.05 |
| PVPK30(元) | 296,151,181.08 | 159,896,513.94 | 256,611,952.68 | 99,548,500.24 |
| 分子诊断服务(元) | 11,521,410.49 | 6,020,504.47 | 9,534,177.23 | 4,393,098.85 |
| 基因检测技术服务(元) | 13,824,749.31 | 10,950,883.74 | 11,642,038.78 | 5,108,821.74 |
| 欧瑞姿系列(元) | 118,512,243.13 | 50,081,320.86 | 113,460,420.90 | 44,984,533.10 |
| 医疗服务(元) | 17,140,661.05 | 9,478,337.35 | 15,373,135.20 | 5,149,655.25 |
| PVP系列其他产品(元) | 380,374,912.68 | 194,466,479.90 | 232,619,715.37 | 128,340,463.04 |
| 肿瘤早期诊断(元) | 29,636,997.87 | 14,053,944.37 | 23,646,500.51 | 10,814,098.41 |
| 生命科学研究试剂(元) | - | - | - | - |
| 其他主营业务(元) | - | - | - | 10,814,098.41 |
| 毛利率(%) | ||||
| PVP-I(%) | 39.68 | 36.92 | 40.85 | 44.24 |
| PVPK30(%) | 53.69 | 55.78 | 43.33 | 34.98 |
| 分子诊断服务(%) | 35.98 | 37.71 | 28.84 | 28.85 |
| 基因检测技术服务(%) | 22.64 | 33.49 | 17.72 | 17.47 |
| 欧瑞姿系列(%) | 75.59 | 64.96 | 71.71 | 65.23 |
| 医疗服务(%) | 27.37 | 24.25 | 25.18 | 21.79 |
| PVP系列其他产品(%) | 63.17 | 71.05 | 49.81 | 63.26 |
| 肿瘤早期诊断(%) | 61.03 | 61.09 | 58.42 | 58.80 |
| 生命科学研究试剂(%) | - | - | - | - |
| 其他主营业务(%) | - | - | - | 58.80 |
| 收入构成(%) | ||||
| PVP-I(%) | 4.33 | 3.96 | 4.57 | 5.09 |
| PVPK30(%) | 34.83 | 36.80 | 39.86 | 40.84 |
| 分子诊断服务(%) | 2.02 | 2.05 | 2.22 | 2.19 |
| 基因检测技术服务(%) | 3.86 | 4.20 | 4.42 | 4.20 |
| 欧瑞姿系列(%) | 9.90 | 9.90 | 10.65 | 9.90 |
| 医疗服务(%) | 3.96 | 5.02 | 4.11 | 3.39 |
| PVP系列其他产品(%) | 38.03 | 35.13 | 31.43 | 29.11 |
| 肿瘤早期诊断(%) | 3.07 | 2.95 | 2.72 | 2.64 |
| 生命科学研究试剂(%) | - | - | 0.00 | - |
| 其他主营业务(%) | - | - | - | 2.64 |
| 毛利构成(%) | ||||
| PVP-I(%) | 3.04 | 2.49 | 4.02 | 4.83 |
| PVPK30(%) | 33.11 | 35.04 | 37.16 | 30.64 |
| 分子诊断服务(%) | 1.29 | 1.32 | 1.38 | 1.35 |
| 基因检测技术服务(%) | 1.55 | 2.40 | 1.69 | 1.57 |
| 欧瑞姿系列(%) | 13.25 | 10.97 | 16.43 | 13.85 |
| 医疗服务(%) | 1.92 | 2.08 | 2.23 | 1.59 |
| PVP系列其他产品(%) | 42.53 | 42.62 | 33.68 | 39.51 |
| 肿瘤早期诊断(%) | 3.31 | 3.08 | 3.42 | 3.33 |
| 生命科学研究试剂(%) | - | - | 0.00 | - |
| 其他主营业务(%) | - | - | - | 3.33 |